Drug Approval | October 01, 2024
Apitoria Pharma gets Form 483 with 10 observations from USFDA
The observations are of procedural in nature and will be responded to within the stipulated time
The observations are of procedural in nature and will be responded to within the stipulated time
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples
These accolades highlight our unwavering commitment to maintaining the highest safety standards
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Subscribe To Our Newsletter & Stay Updated
